## SYK: Stryker Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.4% below STRENGTH zone (3.0-6.0%); PEG 1.46 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($341.42)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 1)

**1. Truist Financial Maintains Stryker Corp(SYK.US) With Hold Rating, Announces Target Price $392**
- Source: 富途牛牛 | 20251218T180847 | Neutral | Relevance: 100%
- Truist Financial analyst Richard Newitter has reaffirmed a "hold" rating for Stryker Corp (SYK.US) and set a target price of $392. Newitter boasts a 54.7% success rate and a 13.9% average return over the past year, according to TipRanks data. This rating indicates that Truist Financial sees Stryker Corp's stock maintaining its current value without significant upward or downward movement in the near future.

**2. What Makes Stryker Corp. (SYK) a High-Quality, Defensive Compounder?**
- Source: Finviz | 20251218T160836 | Bullish | Relevance: 100%
- Parnassus Investments' Value Equity Fund highlighted Stryker Corporation (NYSE:SYK) in its Q3 2025 investor letter, recognizing it as a high-quality, defensive compounder. Despite recent underperformance, the company's growth is driven by new product launches in its MedSurg segment and increasing adoption of its robotic surgery platform. The fund also anticipates continued profitability improvements under CEO Kevin Lobo.

**3. RBC Capital Maintains Stryker Corp(SYK.US) With Buy Rating, Maintains Target Price $435**
- Source: 富途牛牛 | 20251218T040922 | Bullish | Relevance: 100%
- RBC Capital analyst Shagun Singh Chadha has reiterated a Buy rating for Stryker Corp (SYK.US) and maintained the target price at $435. The analyst's past performance shows a 50.4% success rate and an average return of 2.7% over the last year, according to TipRanks data. This rating indicates continued confidence in Stryker Corp's stock performance.

**4. CCORF Maintains Stryker Corp(SYK.US) With Buy Rating, Maintains Target Price $435**
- Source: 富途牛牛 | 20251217T190847 | Bullish | Relevance: 100%
- CCORF analyst Caitlin Cronin has reiterated a "buy" rating for Stryker Corp (SYK.US) and maintained a target price of $435. According to TipRanks data, this analyst has shown a 57.9% success rate and an average return of 15.7% over the past year. The information provided is for informational purposes only and does not constitute investment advice.

**5. Could Stryker’s (SYK) Leadership Shuffle and Higher Dividend Reframe Its Long‑Term Growth Narrative?**
- Source: Simply Wall Street | 20251217T112546 | Somewhat-Bullish | Relevance: 100%
- Stryker (SYK) recently announced a quarterly dividend increase of 4.8% and key leadership changes, including Spencer Stiles as President and COO and Dylan Crotty as Group President of Orthopaedics. These moves, coupled with growth in cranio maxillofacial fixation devices, aim to reinforce Stryker's long-term growth driven by innovation and higher procedure volumes. The article explores how these developments might impact the company's investment narrative and future growth assumptions, noting that regulatory risks in Europe remain a key factor.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Citizens | $440 | $0 | 0% |
| 2025-12-18 | Truist Securiti | $392 | $400 | -2% |
| 2025-12-11 | Citigroup | $420 | $455 | -8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Citizens | up | Market Outperform |
| 2025-12-18 | Truist Securiti | main | Hold |
| 2025-12-11 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.76M) |
| Sells | 7 ($21.05M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (+0.8%)
- Blackrock Inc.: 7.0% (+0.4%)
- JPMORGAN CHASE & CO: 6.2% (+95.3%)
- Greenleaf Trust: 4.3% (-0.3%)
- State Street Corpora: 3.9% (-0.1%)

### Key Risks

1. Heavy insider selling: $21M sold (7 transactions in 90 days).
2. Long-term trend broken: trading 5.4% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.46 suggests fair value with growth premium. Forward P/E 23.8x stretched relative to 10% growth. Balance sheet: $1.4B free cash flow. Analyst sentiment negative (2 target cuts vs 0 raises). Insider selling cluster ($21.1M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $135.8B |
| Beta | 0.90 |
| 52W Range | $329.16 - $406.19 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.46 |
| Forward P/E | 23.8 |
| Current P/E | 26.2 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 weakening modestly (-0.6% over 5 days). Below STRENGTH zone by 2.6pp (needs >3.0% for momentum thesis). MRS_5 (-0.8%) diverging from MRS_10 - short-term weakness emerging. Below SMA200 (0.95x), long-term trend not supportive. RSI neutral at 44. OFD pattern: +DBH (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.36% (CS: 61) | Neutral |
| RSI_14 | 43.5 | Neutral |
| MACD Histogram | -0.46 | Bearish |
| vs SMA20 | 0.983x | Below |
| vs SMA50 | 0.972x | Below |
| vs SMA200 | 0.946x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $354.98
- **Stop Loss:** $341.42 (3.8% risk)
- **Target:** $368.54 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 88
- **Position Value:** $31,238.24
- **Portfolio %:** 31.24%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-01-27 (Est: $4.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.13 | $3.19 | +1.9% |
| 2025Q2 | $3.07 | $3.13 | +1.9% |
| 2025Q1 | $2.73 | $2.84 | +4.0% |
| 2024Q4 | $3.87 | $4.01 | +3.5% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*